Narhex Life Sciences Limited has executed a formal Share Sale Agreement to acquire 100% of ResApp Diagnostics Pty Ltd (“ResApp”).
ResApp, through the exclusive licence it has been granted by the University of Queensland (“UQ”), is developing smart phone medical applications for the diagnosis and management of respiratory disease. The technology is based on a machine learning algorithm that uses sound alone without the need for additional hardware to diagnose and measure the severity of a respiratory condition. The algorithm has been successfully tested for pneumonia and asthma diagnosis in a clinical proof of concept study of 91 patients by UQ through funding from the Bill and Melinda Gates Foundation.
The commencement of a new trial at Joondalup Health Campus was featured on Channel 7’s Today Tonight on Monday, 23 March 2015 - https://www.youtube.com/watch?v=sazdLMFPey8